Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 3 of 89 for:    Developmental Disabilities | ( Map: Canada )

Assessing Suicide Risk in Adolescents With Developmental Delays

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01517126
Recruitment Status : Terminated (slow accrual)
First Posted : January 25, 2012
Last Update Posted : September 18, 2019
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )

Brief Summary:


- Currently, there is no standard method to study suicide risk in youth with developmental delays or intellectual disabilities (DD/ID). Youth with DD/ID are often excluded from studies that are used to develop these methods. As a result, most current suicide risk assessments have not been tested for use with people with DD/ID. Researchers want to develop an effective suicide risk screening tool for children and adolescents with DD/ID.


- To develop a suicide risk screening tool for young adults with DD/ID.


  • Young adults between 12 and 21 years of age who have DD/ID and are in mental health counseling.
  • Participants will be in counseling at Surrey Place Centre, a community health center in Toronto, Canada.


  • Participants will fill out questionnaires during a 1-hour meeting with a therapist. The questions will ask about mood and current feelings, including whether the participant has been thinking about or planning to hurt or kill him or herself now or in the past. Other questions will ask about participants' understanding of death in general.
  • Parents of participants may also fill out a questionnaire. It will ask about how the participant has been feeling. It will also ask whether the parent has noticed any signs that suggest suicidal thoughts or actions, now and in the past.
  • Treatment will not be provided as part of this protocol. However, participants can receive counseling through the regular Surrey Place Centre services.

Condition or disease
Child Development Disorders, Pervasive

Detailed Description:


Currently, no gold standard is available for evaluating suicidal thoughts and behaviors in individuals with developmental delay or intellectual disabilities (DD/ID). Moreover, youth with DD are often excluded from instrument validation studies. Therefore, there is a paucity of sufficiently adapted and validated clinical suicide risk assessments for use with clients with DD/ID. The main objective of this study is to develop and assess the efficacy of a suicide screening tool for child and adolescent clients with DD/ID. More specifically:

Aim 1: To modify the Risk of Suicide Questionnaire (RSQ) in order to create a suicide screening tool for a pediatric mental health population with DD/ID.

Aim 2: To determine the feasibility of a suicide screening tool, (developed in Aim 1) to detect suicide risk in pediatric clients with DD/ID presenting to a community health center for mental health reasons.

Study population:

The NIMH is collaborating with Surrey Place Centre, a community health center in Toronto, Canada. The study population will be Surrey Place Centre clients, ages 12 and older, diagnosed with DD/ID, currently accessing individual mental health counseling. There will be no exclusion based on gender or race.


This will be a prospective instrument development study. Potential participants will be identified by research assistants (RAs) and therapists. Following informed consent and assent procedures, therapists will administer the Risk of Suicide Questionnaire Intellectual Disability Patient (RSQ-ID-Patient), and the Suicidal Ideation Questionnaire Child Version (SIQ-CV) to clients, and the RA will have the parents/guardians complete the Risk of Suicide Questionnaire-Intellectual Disability-Parent (RSQ-ID Parent). Three months after client participation, therapists will fill out a Therapist Follow-up Questionnaire.

Outcome measures:

Primary outcome measures include the RSQ-ID Patient, and the SIQ-CV, along with the RSQ-ID Parent. Secondary outcome measure is the Research Assistant Evaluation Form and the Clinician Follow- up Form.

Layout table for study information
Study Type : Observational
Actual Enrollment : 17 participants
Time Perspective: Prospective
Official Title: Assessing Suicide Risk in Adolescents With Developmental Delays: Development of a Screening Tool
Study Start Date : January 6, 2012
Actual Primary Completion Date : September 13, 2019
Actual Study Completion Date : September 13, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Suicide

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Client must be enrolled in individual counseling at the Surrey Center at time of participation and must have attended at least 3 therapy appointments.

Clients must have an IQ score betwen 55 and 75 (a range considered to "mild developmental delay"). A client with mild DD will have the ability to communicate verbally and provide writtent assent. In order to receive services at Surrey Place Centre, clients must have a designation of "developmental delay" with and IQ score or range. If they do not have an IQ Score or DD designation, they undergo assessment at intake. Therefore, each client will have an IQ score recorded prior to study recruitment.

Age 12 years or older

English speaking

A legal guardian must provide informed consent and client must sign an assent document. Verbal assent is not acceptable for participation.


Legal guradian is non-English speaking and no translation support is available to assist with the consent process.

No IQ score on record.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01517126

Layout table for location information
Surrey Place Centre
Toronto, Canada
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Lisa M Horowitz, Ph.D. National Institute of Mental Health (NIMH)

Layout table for additonal information
Responsible Party: National Institute of Mental Health (NIMH) Identifier: NCT01517126    
Other Study ID Numbers: 999912034
First Posted: January 25, 2012    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):
Youth Suicide
Suicide Screening
Developmental Delay
Intellectual Disability
Assessment Instrument
Mental Retardation
Suicidal Thoughts
Suicidal Behavior
Additional relevant MeSH terms:
Layout table for MeSH terms
Developmental Disabilities
Child Development Disorders, Pervasive
Self-Injurious Behavior
Behavioral Symptoms
Neurodevelopmental Disorders
Mental Disorders